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Abstract The Fragile X syndrome (FXS) is a leading cause
of intellectual disability (ID) and autism. The disease is
caused by mutations or loss of the Fragile X Mental
Retardation Protein (FMRP), an RNA-binding protein
playing multiple functions in RNA metabolism. The
expression of a large set of neuronal mRNAs is altered
when FMRP is lost, thus causing defects in neuronal
morphology and physiology. FMRP regulates mRNA
stability, dendritic targeting, and protein synthesis. At
synapses, FMRP represses protein synthesis by forming a
complex with the Cytoplasmic FMRP Interacting Protein 1
(CYFIP1) and the cap-binding protein eIF4E. Here, we
review the clinical, genetic, and molecular aspects of FXS
with a special focus on the receptor signaling that regulates
FMRP-dependent protein synthesis. We further discuss the
FMRP–CYFIP1 complex and its potential relevance for ID
and autism.
Keywords Fragile X syndrome.Autism.FMRP.Protein
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Fragile X and fragile X tremor ataxia syndromes:
clinical phenotypes
The Fragile X syndrome (FXS) is the most frequent form of
inherited intellectual disability (Jacquemont et al. 2007).
Patients with FXS have physical features, such as large
ears, an elongated face, and a high arched palate, which
have been reported in 60% of prepubertal FXS boys. Other
symptoms include connective tissue anomalies, which can
lead to a prolapsed mitral valve, scoliosis, flat feet, and
joint laxity and macro-orchidism in boys. Macro-orchidism
affects about 90% of boys with FXS (Jacquemont et al.
2007) but the causes are still largely unknown. In addition,
subtle dysfunctions of the hypothalamic-pituitary-thyroid
axis have been reported in FXS patients (Bregman et al.
1990). Studies performed in Fmr1 KO animals did not
reveal altered levels of the follicle-stimulating hormone, but
an increase of Sertoli cell proliferation during testis
development (Slegtenhorst-Eegdeman et al. 1998).
Patients display a broad spectrum of cognitive and
behavioral deficits. The developmental delay is the most
consistent feature, with a mean IQ of 42 in boys and severe
mental retardation inabout 25% ofcases.Since the disorderis
X-linked and the penetranceis variable, females are usually in
a low-normal range, with an IQ ranging from 70 to 90
(Jacquemont et al. 2007). Moreover, epilepsy has been
described in 13–18% of boys and 4% in girls, but the
seizures tend to resolve during childhood (Berry-Kravis
2002). Despite the severe neurobehavioral symptoms, the
anatomical studies only revealed minor abnormalities in post
mortem brains from FXS patients (Hallahan et al. 2011;
Reiss et al. 1995). The most prominent neuroanatomical
feature is the dysgenesis of dendritic spines that appear
longer and thinner than normal, likely due to a developmen-
tal delay in spine dynamics and in transition from immature
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FXS is also considered the most common monogenic cause
of Autism Spectrum Disorder, ASD (Hatton et al. 2006)( s e e
below).
FXS is mainly due to a triplet repeat expansion in the 5′
untranslated region (5′UTR) of the Fragile X mental
retardation 1 (FMR1) gene, located on chromosome
Xq27-3. In over 90% of patients, a CGG triplet in the 5′
UTR of the gene is expanded to over 200 copies, leading to
hypermethylation of the CGG, transcriptional silencing, and
abolished production of the Fragile X Mental Retardation
Protein (FMRP) (Jacquemont et al. 2007). Cases of FXS
due to point mutations or microdeletions are very rare. A
severe FXS form has been documented in a patient with a
mutation in the coding region, leading to the substitution of
Isoleucine 304 to Asparagine (Ile304Asn) (De Boulle et al.
1993). A few cases of deletions in the coding regions have
also been identified (Gedeon et al. 1992; Meijer et al. 1994;
Mila et al. 2000; Wohrle et al. 1992).
The CGG triplet region is highly polymorphic in the
population. Normal alleles (5–44 CGG copies) are stably
transmitted to the offspring; “grey-zone” alleles (45–54
copies), and “premutation” alleles (55–200 copies) are
rather unstable and can evolve into a “full mutation” (>200
repeats) during the maternal transmission. The risk of
transmitting a full mutation allele is a function of the repeat
length (Hagerman and Hagerman 2002).
Premutation alleles do not lead to FXS, but can cause two
distinct pathologies, namely the Fragile X-associated Prema-
ture Ovarian Insufficiency (FX-POI) and the Fragile
X-associated Tremor/Ataxia Syndrome (FXTAS). FX-POI is
defined as menopause or hypoestrogenic amenorrhea occur-
ring prior to age 40. Premature ovarian failure occurs in about
1% of the general population, and about 6% of women with
this disease are positive for premutation alleles (Hagerman
and Hagerman 2002). FXTAS is a neurodegenerative
disorder mainly featured by progressive cerebellar ataxia
and intention tremor. The patients also show neuropsychiat-
ric alterations (anxiety, hostility, depression) and cognitive
dysfunctions, ranging from mild frontal executive and
memorydeficitstoglobaldementia(HagermanandHagerman
2002; Jacquemont et al. 2007). Although FXTAS mainly
affects men, clinical cases of women with FXTAS have also
been reported (Hagerman et al. 2004).
The molecular mechanisms underlying the premutation
pathologies are not fully understood. A consistent molec-
ular feature is the elevation of FMR1 mRNA levels (Allen
et al. 2004; Kenneson et al. 2001; Tassone et al. 2000) due
to increased transcription (Tassone et al. 2007). Neverthe-
less, carriers of premutation alleles show decreased levels
of FMRP (Brouwer et al. 2008; Entezam et al. 2007;
Kenneson et al. 2001; Primerano et al. 2002) caused by
reduced translational efficiency of the FMR1 mRNA due to
the CGG expansion in the 5′UTR (Feng et al. 1995;
Primerano et al. 2002) as well as polyadenylation (Tassone
et al. 2011). Additionally, FMR1 mRNA has been detected
in the ubiquitin-positive intranuclear inclusions found in
neurons and astrocytes throughout the brain of FXTAS
patients (Greco et al. 2002; Tassone et al. 2004). The
intranuclear foci were consistently observed in model
organisms for FXTAS, both mouse (Berman and Willemsen
2009) and Drosophila (Jin et al. 2007; Sofola et al. 2007).
Remarkably, the number of inclusions correlates with the
size of the CGG expansion (Greco et al. 2006; Greco et al.
2002). These observations led to the hypothesis that the
premutation causes a gain-of-function phenotype due to
RNA toxicity (Brouwer et al. 2009; Garcia-Arocena and
Hagerman 2010; Tan et al. 2009).
Fragile X syndrome and Autism Spectrum Disorder FXS is
the most common monogenic cause of Autism Spectrum
Disorder (ASD), a heterogenous group of neurodevelopmental
pathologies affecting approximately 37 individuals in 10,000
(Fombonne 2005) and observed in more than 40% of patients
with intellectual disability (Moss and Howlin 2009). ASD is
diagnosed by clinical assessment of three core dysfunctions
before 3 years of age: atypical social behavior, deficits in
verbal and non-verbal communication, and presence of
repetitive and highly restricted interests (Geschwind and
Levitt 2007). These disturbances range from the Autistic
Disorder (13 in 10000), through a Pervasive Developmental
Disorder Not Otherwise Specified (PDD-NOS, 20.8 in
10000), to a less frequent form, the Asperger syndrome (2.6
in 10000) (Fombonne 2005). However, while children with
Autistic Disorder and PDD-NOS have specific impairments in
the three domains (language, social and interests) and can be
mentally retarded, individuals with Asperger Syndrome have
a proper use of language and are not affected by cognitive
delay (Abrahams and Geschwind 2008).
About 25% of FXS boys and 6% of girls have been
reported to meet criteria for ASD, while 1–2% of patients
affected by ASD have FXS (Abrahams and Geschwind 2008;
Hatton et al. 2006). Recent reports estimated that about 30%
of FXS subjects meet criteria for Autistic Disorder and 30%
for PDD-NOS (Harris et al. 2008). However, up to 90% of
children with Fragile X display behavioral alterations which
resemble ASD, such as social anxiety, gaze avoidance,
sensory hypersensitivity, tactile defensiveness, stereotypic
movements, poor motor coordination, delayed speech devel-
opment, and echolalia (Belmonte and Bourgeron 2006;
Hernandez et al. 2009). The basis of reduced penetrance of
ASD in patients with FXS is still unclear; nevertheless, the
cognitive delay is more severe in FXS children with ASD,
and children with FXS and ASD are more likely to have a
secondary medical problem compared to those with FXS
alone (Garcia-Nonell et al. 2008).
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Fragile X syndrome is caused by the absence of the Fragile
X Mental Retardation Protein (FMRP). FMR1 mRNA is
ubiquitously expressed, and high levels have been detected
in brain and gonads—the organs mainly affected in FXS
patients (Tamanini et al. 1997). Considering the correlation
between FMRP expression and cognitive abilities, the
molecular role of this protein has been deeply investigated
in brain.
Functionally, FMRP belongs to the family of RNA
binding proteins (RBPs), which shuttle between nucleus
and cytoplasm. As other RBPs, FMRP interacts with
protein partners and RNAs forming large messenger
ribonucleoparticles (mRNPs). FMRP has four RNA binding
domains and can associate with messenger RNAs, as well
as noncoding RNAs, such as the Brain Cytoplasmic 1
(BC1) RNA and microRNAs (Edbauer et al. 2010; Gabus et
al. 2004; Johnson et al. 2006; Zalfa and Bagni 2005; Zalfa
et al. 2003). Among the best characterized FMRP targets
are α-CaMKII, Arc, Map1b, Sapap4,a n dPSD-95 mRNAs
(Bassell and Warren 2008) (Table 1). While some mRNAs
such as PSD-95 are directly recognized by FMRP (Zalfa et
al. 2007), some others are recruited through base-pairing
with noncoding RNAs such as BC1 (Zalfa et al. 2005; Zalfa
et al. 2003) and microRNAs (Edbauer et al. 2010).
Furthermore, FMRP mRNPs orchestrate the posttranscrip-
tional destiny of bound mRNAs by regulating their stability,
localization, or translation (Bagni and Greenough 2005;D e
Rubeis and Bagni 2010) (Table 1).
Effects of FMRP on mRNA stability FMRP can regulate
mRNAs half-life, either by favoring or preventing mRNA
decay (De Rubeis and Bagni 2010). Two high-throughput
screenings revealed that FMRP affects the expression of
target mRNAs. First, Warren and colleagues found that the
levels of 144 target mRNAs were changed in lymphoblas-
toid cells from FXS patients (Brown et al. 2001). In a
second study, Eberwine and collaborators reported de-
creased expression levels of at least 2 mRNAs (p40/LRP
and GRK4 mRNAs) in the hippocampus of Fmr1 KO mice
(Miyashiro et al. 2003). Furthermore, loss of FMRP may
affect the expression of mRNAs encoding GABAA recep-
tors. The expression of δ subunit mRNA, previously
identified as FMRP target by Miyashiro et al. (2003), was
found to be reduced in FMRP-deficient neurons in a
Table 1 FMRP functions and target mRNAs
FMRP
Function
Regulation Target MRNAS Where FMRP affects
their regulation
How FMRP affects
their regulation
References
Stability + PSD-95 Mouse hippocampus Activity-dependent Zalfa et al. 2007
+ GABA subunits Mouse cortex; Drosophila. mRNA levels are reduced
but a direct evidence on
their different stability
is not available
Gantois et al. 2006;
D’Hulst et al. 2006;
Dictenberg et al. 2008
Transport + Map1B Primary hippocampal neurons Activity-driven transport Dictenberg et al. 2008
+ α-CaMKII Primary hippocampal neuron Activity-driven transport Dictenberg et al. 2008;
Kao et al. 2010
+ Sapap4 Primary hippocampal neurons Activity-driven transport Dictenberg et al. 2008
+ Rgs5 Hippocampal slices Basal mRNA localization Miyashiro et al. 2003
Translation − Map1B Mouse brain and hippocampal
slices; human FXS
lymphoblastoid cells;
Basal and activity-dependent Brown et al. 2001;
Zalfa et al. 2003;
Lu et al. 2004;
Hou et al. 2006
− Arc Mouse brain; hippocampal
slices; synaptoneurosomes
Basal and activity-dependent Zalfa et al. 2003;
Park et al. 2008
− α-CaMKII Mouse brain; hippocampal
slices; synaptoneurosomes
Basal and activity-dependent Zalfa et al. 2003;
Hou et al. 2006;
Muddashetty et al. 2007;
Kao et al. 2010
− App Cortical synaptoneurosomes Basal and activity-dependent;
antagonistic effects with
HnRNPC
Westmark and Malter 2007;
Lee et al. 2010
− PSD-95 Cortical synaptoneurosomes Activity-dependent Todd et al. 2003;
Muddashetty et al. 2007
Three well-characterized FMRP functions, namely mRNA stability, transport and translation, are indicated. Established FMRP target mRNAs are
listed. Other studies on additional putative mRNA targets are cited in the text
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2006) as well as by in situ hybridization studies (Dictenberg
et al. 2008). Additionally, the mRNAs encoding 8 out of 18
known GABA subunits (α1, α3, α4, β1, β2, γ1, γ2a s
well as the above mentioned δ) are significantly reduced in
cortex, but not in cerebellum, of Fmr1 KO mice (D’Hulst et
al. 2006). Similar results were obtained for the three
subunits conserved in Drosophila (D’Hulst et al. 2006).
However, further studies are required to address if this
regulation is directly or indirectly mediated by FMRP .
Finally, two recent reports have implicated FMRP as
a direct modulator of mRNA turnover. First, FMRP
through its C terminus domain recognizes a G-rich
structure in the 3′UTR of PSD-95 mRNA and protects it
from decay. This effect, observed only in hippocampus
and not in cortex, leads to decreased PSD-95 mRNA
expression in Fmr1 KO animals. Of note, the stabilizing
function of FMRP is promoted after the activation of the
group I metabotropic glutamate receptors (mGluRs) with
the agonist (S)-3,5-dihydroxyphenylglycine (DHPG)
(Zalfa et al. 2007). Furthermore, the region-specific effect
of FMRP on PSD-95 mRNA stability is consistent with
other reports showing that PSD-95 mRNA synaptic
translation is affected in cortical synaptoneurosomes of
FMRP-lacking mice (Muddashetty et al. 2007;T o d de ta l .
2003). This leads to the hypothesis that (1) different
molecular complexes act, together with FMRP , in cortex
and hippocampus; (2) FMRP regulates mRNAs differen-
tially in cell soma and at synapses. Second, in a mouse
neuroblastoma cell line, FMRP favors the decay of Nxf1
mRNA acting in concert with the nuclear export factor
N X F 2( Z h a n ge ta l .2007). Upon NXF2 overexpression,
Nxf1 mRNA is rapidly degraded, but this effect is
obstructed by silencing FMRP; this would suggest that
FMRP mediates the degradation of Nxf1 mRNA induced
by NXF2 (Zhang et al. 2007).
Effects of FMRP on mRNA dendritic transport FMRP can
also modulate the targeting of mRNAs in subcellular
domains far away from the cell body, such as dendrites
and spines. While travelling along the dendrites, the
mRNAs are thought to be translationally silent; after
synaptic stimulation, the mRNPs can be docked to the
spines and protein synthesis ensues (Bramham and Wells
2007). FMRP is present along the dendritic shaft, at the
basis of the spines (Antar et al. 2004; Feng et al. 1997;
Ferrari et al. 2007), in growth cones and mature axons
(Antar et al. 2006; Centonze et al. 2008; Price et al. 2006).
The synaptic distribution of FMRP increases upon the
activation of the group I mGluRs. In fact, in response to
DHPG, the dendritic transport of Fmr1 mRNA is
enhanced, and FMRP is newly synthesized in close
proximity to mGluR5 (Antar et al. 2004; Ferrari et al.
2007; Kao et al. 2010); in addition, FMRP is further
recruited by travelling along the microtubules (Antar et al.
2004; Antar et al. 2005; Dictenberg et al. 2008; Ferrari et
al. 2007; Kanai et al. 2004). In mammals, FMRP has been
reported to interact with the motor proteins kinesin 5
(KIF5) and 3C (Dictenberg et al. 2008; Kanai et al. 2004;
Davidovic et al. 2007); in Drosophila,F M R Ph a sb e e n
f o u n dw i t hk i n e s i na n dd y n e i n( L i n ge ta l .2004). In the
model proposed by Dictenberg and colleagues, upon
DHPG stimulation, FMRP would interact more efficiently
with the kinesin light chain, a major cargo-binding subunit
of KIF5, thus promoting the activity-dependent localiza-
tion of bound mRNAs. Therefore, the stimulus-induced
dendritic targeting of some mRNAs such as Map1b,
α-CaMKII,a n dSapap4 is compromised in Fmr1 KO
hippocampal neurons (Dictenberg et al. 2008). This report
is in agreement with previous in vivo studies by Steward
and colleagues showing that mRNA transport is not
affected in basal condition (Steward et al. 1998).
Recently, a time-lapse imaging study revealed that the
dendritic granules containing Fmr1 and α-CaMKII mRNAs
undergo decelerated motion within 0–40 min after DHPG
stimulation, likely due to docking of these mRNAs to the
spines. Consistently, α-CaMKII mRNA distribution in spines
increases upon DHPG application to adjacent dendrites. Both
effects are abolished in FMRP deficient neurons (Kao et al.
2010). This piece of evidence suggests that FMRP not only
contributes to mRNA transport along dendrites, but also to
activity-induced docking of the mRNAs in the spines.
Effects of FMRP on protein synthesis In highly polarized
cells like neurons, protein synthesis occurs not only in the
soma, but also along dendrites, axons, and at synapses.
While polyribosomes, translational factors, and specific
mRNAs have been detected at post-synaptic sites (Bramham
and Wells 2007; Steward and Schuman 2003), consider-
able evidence indicates regulation of axonal protein
synthesis as well (Holt and Bullock 2009). De novo
protein synthesis at synapses is a critical event underlying
long-lasting forms of synaptic plasticity, required for
consolidation and storage of long-term memories. In fact,
BDNF-induced Long Term Potentiation (LTP) in hippo-
campal brain slices can be blocked by translational
inhibitors, even when the pre- and post-synapses are
severed from the soma (Kang and Schuman 1996).
Another form of synaptic plasticity, mGluR-dependent
Long Term Depression (mGluR-LTD), also depends on
local protein synthesis (Huber et al. 2000).
Remarkably, FMRP is implicated in both basal and
activity-dependent local protein synthesis (Hou et al. 2006;
Kao et al. 2010; Lu et al. 2004; Muddashetty et al. 2007;
Napoli et al. 2008;P a r ke ta l .2008; Zalfa et al. 2003).
FMRP represses translation both in vitro (Laggerbauer et al.
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2004; Muddashetty et al. 2007;N a p o l ie ta l .2008;
Narayanan et al. 2007; Park et al. 2008; Zalfa et al.
2003). The properties of FMRP as translational regulator
have been widely investigated through the biochemical
fractionation of brain extracts in actively translating
ribosomes (polysomes) and translationally silent particles
(mRNPs). These studies revealed that more than 200 FMRP
target mRNAs display an abnormal polysome/mRNP
distribution in lymphoblastoid cells from individuals with
FXS, indicative of altered translation (Brown et al. 2001).
In the brain from Fmr1 KO mice, several mRNAs including
α-CaMKII, Arc, Map1b are preferentially distributed on
polysomes rather than on mRNPs as result of excessive
translation. Accordingly, the levels of the proteins encoded
by those mRNAs are significantly increased in the absence
of FMRP (Zalfa et al. 2003). In addition, these changes are
also present in purified synaptoneurosomes (Muddashetty
et al. 2007; Zalfa et al. 2003), extending the function of
FMRP as a repressor to synapses. In response to DHPG
stimulation, however, FMRP-mediated inhibition of α-CaM-
KII mRNA is rapidly released; this activity-dependent
response is abolished in the absence of FMRP (Hou et al.
2006; Kao et al. 2010; Muddashetty et al. 2007). Finally, a
high-throughput proteomic study recently showed that the
expression of over 100 proteins is altered in synaptoneur-
osomes isolated from Fmr1 KO neurons, possibly due to
affected dendritic mRNA localization and protein synthesis
(Liao et al. 2008). At the level of the synaptic compartment,
local protein synthesis can be coupled with membrane
receptors. It has been demonstrated that DCC, the receptor
for the axonal guidance factor netrin, anchors components of
the translational machinery in growth cones, filopodial tips,
and at synapses (Tcherkezian et al. 2010). In addition, FMRP
interacts with the sodium-activated potassium channel Slack-
B and recruits some co-interacting mRNAs (Map1b and Arc
mRNAs) to the channel (Brown et al. 2010). Therefore, it is
tempting to hypothesize that FMRP is not only implicated in
the regulation of local translation, but also couples it to
synaptic membrane receptors.
The complex FMRP regulation downstream receptor
activation has been investigated by several laboratories and
is summarized in Fig. 1.
FMRP form different mRNP particles The mechanisms
responsible for FMRP-dependent protein synthesis are still
debated. To investigate this aspect, the polysome/mRNPs
sedimentation of protein extracts along sucrose gradients
has been used by different laboratories delivering different
results (Zalfa et al. 2006). Initial studies from Dreyfuss'
laboratory showed that in mammalian cells, FMRP is
mainly associated with mRNPs (Siomi et al. 1996).
Following studies detected FMRP either co-fractionating
with polysomes (Ceman et al. 2003; Khandjian et al. 2004;
Stefani et al. 2004) or with mRNPs (Ishizuka et al. 2002;
Monzo et al. 2006; Napoli et al. 2008; Papoulas et al. 2010;
Siomi et al. 1996; Zalfa et al. 2003) or equally distributed
between polysomes and mRNPs (Brown et al. 2001).
FMRP can associate with many nuclear and cytoplasmic
partners forming different neuronal granules, including P
bodies, stress granules, and transport granules (Anderson
and Kedersha 2006; Kanai et al. 2004; Zalfa et al. 2006).
This suggests that FMRP can take part in a variety of
mRNPs and is possibly influenced by its phosphorylation
state (Ceman et al. 2003). Importantly for the physiology of
the FMRP complexes, both P bodies and stress granules do
not contain large ribosomal subunits and polysomes
(Anderson and Kedersha 2006). Furthermore, the distribu-
tion of FMRP on both mRNPs and polysomes could
account for different functions of FMRP in either repressing
or activating translation (Zalfa et al. 2006). In agreement
with this hypothesis, Brown and colleagues found that out
of 251 mRNAs displaying different polysomal distribution
in cells from FXS patients, 136 were increased on
polysomes and 115 decreased (Brown et al. 2001),
suggesting that FMRP might have a dual role in translation.
The FMRP-CYFIP1-eIF4E complex: regulation
of translational initiation
The hypothesis that FMRP is implicated in the repression
of translational initiation is supported by the recent
discovery that the Cytoplasmic FMRP Interacting Protein
1 (CYFIP1) acts as an eIF4E-binding protein (Napoli et al.
2008). CYFIP1, also known as Specifically Rac1 Activated
protein 1 (SRA-1), was identified early as a partner of
FMRP in neurons (Schenck et al. 2003; Schenck et al.
2001). CYFIP1 is also a component of a signaling
machinery controlling the actin cytoskeleton, formed by
the W ASP-family verprolin-homologous (W A VE) (Takenawa
and Suetsugu 2007).
AsproposedbyNapolietal.(2008), CYFIP1 is a neuronal
eIF4E-binding protein (4E-BP). The molecular function of
4E-BPs is to repress mRNA translation by sequestering the
cap-binding protein eIF4E. The 4E-BPs and eIF4G, the
scaffolding protein required for the assembly of the active
initiation complex, share a canonical eIF4E-binding site
(YXXXXLΦ, where X is any amino acid and Φ is a
hydrophobic amino acid) (Costa-Mattioli et al. 2009;
Marcotrigiano et al. 1999), therefore competing for the
binding to eIF4E. As a consequence, the interaction of the
4E-BPs with eIF4E blocks the translation initiation (Fig. 2).
Three canonical 4E-BPs have been identified in mammals.
4E-BP1 is mostly present in adipose tissues and in pancreas,
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littleorno4E-BP1and3(Bankoetal.2005; Klann and Dever
2004). These proteins regulate a large subset of cellular
mRNAs. The translation of a small number of specific
mRNAs can be regulated by other non-canonical 4E-BPs.
Two examples have been so far reported: the Drosophila Cup
and the vertebrate Maskin/Neuroguidin. In such cases, the
4E-BP (Maskin or Neuroguidin, Cup) sequesters eIF4E and
relies on a specific RNA-binding protein (CPEB, and Bruno,
respectively) to inhibit the translation of associated mRNAs
(Richter and Klann 2009)( F i g .2). The CYFIP1-FMRP
complex closely resembles these complexes: in brain and at
synapses, CYFIP1 tethers the mRNAs associated with
FMRP on the eIF4E, thus repressing their translation (Napoli
et al. 2008)( F i g .2). CYFIP1, as well as FMRP and eIF4E,
co-fractionates with mRNPs along sucrose gradients from
mouse brain lysates. Moreover, CYFIP1 associates with the
cap-binding complex in an FMRP-independent manner.
Although CYFIP1 does not have a canonical eIF4E-
binding sequence (YXXXXLΦ), it directly binds eIF4E. In
fact, CYFIP1 possesses a “non canonical” sequence pre-
dicted to form a peculiar “reverse L shaped” structure, which
overlaps with the region of the 4E-BPs fitting into the eIF4E
pocket (Napoli et al. 2008).
TheFMRP-CYFIP1-eIF4EcomplexcontainsBC1 RNA, as
well as several known FMRP target mRNAs, including
Map1b, αCaMKII,a n dApp mRNAs. Since BC1 RNA can
mediate the association of specific mRNAs to FMRP , loss of
BC1 affects, to differing extents, the recruitment of those
mRNAs. Consistent with this evidence, the downregulation of
CYFIP1 in cultured neurons, as well as its genetic depletion in
mouse, causes a significant increase in α-CaMKII, MAP1B,
and APP protein levels (Napoli et al. 2008).
Remarkably, the inhibitory FMRP-CYFIP1-eIF4E com-
plex is present along dendrites and at synapses, but its
formation can be reversed upon neuronal activity (Fig. 3).
The stimulation of synaptoneurosomes with either BDNF
or DHPG favors the release of eIF4E from CYFIP1, thus
Fig. 1 Model for a postsynaptic FMRP signaling. At synapses, FMRP
translational control is released upon TrkB tyrosin kinase signaling
activated by BDNF (Napoli et al. 2008) and/or group I mGluRs
cascade activated by DHPG (Napoli et al. 2008; Narayanan et al.
2007; Narayanan et al. 2008; Osterweil et al. 2010). Two alternative
models have been proposed for the mGluR signaling upstream FMRP .
The first one (A) proposes that the kinase ERK1/2 activation releases
FMRP translational inhibition (Osterweil et al. 2010). The second one
(B) implicates a bimodal PP2A/S6K signaling: an early dephosphor-
ylation by PP2A (B.1) activates translation; sustained DHPG
stimulation activates mTOR pathway (B.2), which suppresses PP2A
activity and stimulates S6K, thus leading to FMRP phosphorylation
and translational block (Narayanan et al. 2007; Narayanan et al. 2008).
Furthermore, activation of group I mGluRs induces an early raise of
FMRP due to protein synthesis (Antar et al. 2004; Ferrari et al. 2007;
Kao et al. 2010) followed by a proteasome-dependent degradation of
the protein (Hou et al. 2006; Zhao et al. 2011), restoring normal
FMRP levels. Early events are indicated with black arrows, while late
events induced by sustained stimulation are indicated by white arrows
262 J Neurodevelop Disord (2011) 3:257–269alleviating the translational block (Napoli et al. 2008). In
conclusion, these data are consistent with a model whereby
FMRP tethers specific mRNAs on CYFIP1, which in turn
sequesters eIF4E and represses translation initiation. Upon
synaptic stimuli, FMRP-CYFIP1 dissociates from eIF4E
and translation is activated (Fig. 3).
The mechanisms reverting the CYFIP1-mediated repres-
sion are unknown. In several cell types, 4E-BPs are
regulated through the extracellular signal-regulated kinase
(ERK), phosphoinositide 3-kinase (PI3K) and mammalian
target of rapamycin (mTOR) pathways (Fig. 1). Upon an
array of stimuli, the activation of the Ser/Thr kinase mTOR
leads to the phosphorylation of several targets, including
the kinase responsible for FMRP phosphorylation, S6K,
and the 4E-BPs. The phosphorylation of the 4E-BPs
disrupts the interaction with eIF4E, therefore relieving the
translational inhibition (Richter and Klann 2009). Further
studies are necessary to determine if CYFIP1 activity can
also be modulated by post-translational modifications.
Translational control and Autism Spectrum Disorder As
discussed, de novo local protein synthesis is required for
synaptic plasticity; in particular, the control of translational
initiation mediated by mTOR signal cascade and 4E-BPs is
critical for the long-lasting changes underlying the consol-
idation and storage of long-term memories. In fact, both
late phase LTP (L-LTP) and mGluR-dependent LTD trigger
mTOR activation, resulting in enhanced 4E-BP2 phosphor-
ylation and increased initiation complex formation (Costa-
Mattioli et al. 2009). Additionally, the mTOR inhibitor
rapamycin blocks long-lasting changes and memory con-
solidation in mammals (Costa-Mattioli et al. 2009). Mice
lacking 4E-BP2 show impaired hippocampal LTP: early
LTP (E-LTP) is converted in late LTP (LTP) and mice
present memory deficits in several behavioral tests (Banko
et al. 2007; Banko et al. 2005). Likewise, mice lacking
FMRP , used as model of FXS, display numerous neuro-
behavioral defects, including enhanced mGluR-dependent
LTD and defective LTP (Hou et al. 2006; Huber et al. 2002;
Meredith et al. 2007; Pfeiffer and Huber 2009). According
to the so-called mGluR theory, the increased LTD in FMRP
deficient mice is due to exaggerated mGluR-dependent
translation; when FMRP is lost, uncontrolled protein
synthesis would result in excessive AMPA internalization
and increased LTD (Bear et al. 2004). A plausible candidate
in this process is Arc mRNA, whose de novo synthesis is
Fig. 2 mRNA translational repression. a General mRNA translation
is repressed by binding of 4E-BP1/2/3 (red) to the cap-binding protein
eIF4E (blue). b Specific translational regulation through sequence
specific regulatory elements. mRNAs harboring the Cytoplasmic
Polyadenylation Element (CPE) are recruited by CPEB (purple) and
their translation repressed by Maskin/Neuroguidin (light blue); c
mRNAs carrying the Bruno-Responsive Element (BRE) are bound by
Bruno (yellow) and their translation inhibited by Cup (orange). d
FMRP (green) can either directly interact with the mRNAs or e recruit
them to the inhibitory complex by base-pairing with the non coding
RNA BC1. In this case, the translation repression occurs via the
eIF4E-BP CYFIP1 (violet)
J Neurodevelop Disord (2011) 3:257–269 263excessive in the absence of FMRP and has been implicated
in AMPA receptors trafficking in response to mGluR-LTD
(Park et al. 2008; Waung et al. 2008; Zalfa et al. 2003). In
support of the mGluR theory, some morphological, phys-
iological, and behavioral features of FXS can be rescued in
model organisms either by administration of a mGluR
antagonist (MPEP) (McBride et al. 2005; Tucker et al.
2006; Yan et al. 2005) or genetic reduction of mGluR5
(Dolen et al. 2007).
The mTOR pathway could play a role in FXS. First, the
fine tuning of the PP2A/S6K activity through the mTOR
signaling modulates the phosphorylation state of FMRP
(Narayanan et al. 2007; Narayanan et al. 2008)( F i g .1).
Second, elevated activity of mTOR pathway has been found
in Fmr1 KO mice (Sharma et al. 2010). In FMRP-lacking
hippocampi, both mTOR phosphorylation and activity are
enhanced, resulting in increased phosphorylation of S6K,
4E-BPs, and consequently eIF4E-eIF4G interaction (Sharma
et al. 2010). This evidence further indicates that FMRP is
involved in modulating translational initiation.
Genetic manipulation of some components of mTOR
signal cascade, such as TSC2, results in synaptic
plasticity defects and behavioral anomalies in mice
(Ehninger et al. 2008a; Hoeffer et al. 2008). Remarkably,
mutations in components of mTOR signaling have been
linked to learning disabilities and ASD (Ehninger et al.
2008b).
Likewise, both CYFIP1 and eIF4E, key components for
the FMRP-regulated protein synthesis, have been correlated
with ASD. CYFIP1 gene is located on a hot spot
chromosomal region for ASD, the 15q11-13 chromosome.
This region lies within the breakpoints (BP) 1 and 3; it is
characterized by a proximal not imprinted region (within
BP1 and BP2), a large imprinted region with several
paternally imprinted and two maternally imprinted genes,
and a distal non-imprinted region. CYFIP1 gene does not
undergo imprinting and, together with other three genes, is
located in the proximal not imprinted region (BP1–BP2).
Altered imprinting of the genes distally to the BP2 can give
rise to three ASD-related syndromes, namely the 15q
duplication syndrome, Angelman Syndrome, and Prader-
Willi Syndrome (Chamberlain and Lalande 2010).
Angelman Syndrome (AS) is due to loss of function of
the maternal copy of the imprinted gene UBE3A. In normal
individuals, only the maternally inherited allele is expressed
in a brain-specific manner, while the paternal copy is
silenced; in patients with AS, the maternal UBE3A is not
longer expressed. AS is characterized by intellectual
disability, deficits in verbal communication, motor dysfunc-
tion, ataxic gait, seizures, cognitive impairment, epilepsy,
Fig. 3 Regulation of the FMRP-
CYFIP1-eIF4E complex. FMRP
(green) binds the mRNAs in a
BC1-dependent or independent
manner and anchors them to
CYFIP1 (violet). CYFIP1 binds
eIF4E (blue), preventing the
formation of active translational
initiation complexes. Upon syn-
aptic stimuli, i.e., activation of
the TrkB (BDNF) or mGluR
(DHPG) receptors, CYFIP1 and
FMRP are released from eIF4E,
which then binds eIF4G allowing
protein synthesis to occur
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flapping movements), and sometimes hyperactivity. On the
other hand, loss of expression of the paternal copy of
several genes paternally imprinted leads to Prader-Willi
Syndrome (PWS). This disease is featured by mild to
moderate cognitive deficit, behavioral problems, and
hyperphagia leading to morbid obesity.
Ofinterest,a subgroupofpatientswithFXSshowsa PWS-
likephenotype withseverehyperphagia,obesity, short stature,
short fingers and toes, and hypogonadism (de Vries et al.
1993; Nowicki et al. 2007). FXS children with Prader-Willi
phenotype do not have cytogenetic alterations of 15q11–13
region, but have a significant reduction in CYFIP1 mRNA
levels compared to FXS individuals without PWS-like
phenotype or unaffected individuals (Nowicki et al. 2007).
As mentioned, CYFIP1 lies within the proximal not
imprinted gene, which includes three other genes,
TUBGPC5, NIP A2,a n dNIP A1. Large deletions of the
15q11–13 region including these four genes lead to more
severe neurobehavioral phenotype in both PWS and AS,
underlining the potential role of these genes in ASD (Butler
et al. 2004; Sahoo et al. 2006). Furthermore, microdeletions
or microduplications of the proximal non-imprinted genes
have been found to co-segregate with cognitive disabilities
and ASD (Doornbos et al. 2009;M u r t h ye ta l .2007; van der
Zwaag et al. 2010). In particular, BP1–BP2 microduplica-
tions are associated with developmental delay, mental
retardation, speech impairment, and behavioral alterations
(ADHD, autism, obsessive-compulsive behavior) (Doornbos
et al. 2009;M u r t h ye ta l .2007). These observations, together
with the functional linkage of CYFIP1 to FXS, point towards
ar o l eo fCYFIP1 in behavioral anomalies and ASD. The
other key partner of the functional FMRP complex, eIF4E,
has been recently implicated in autism as well. Genome-wide
association studies in patients with ASD have indicated
linkage to a region containing the eIF4E gene on chromo-
some 4q (Trikalinos et al. 2006; Yonan et al. 2003).
Moreover, a de novo translocation involving the chromo-
somal region containing eIF4E has been found in a boy
affected by Autistic Disorder (Neves-Pereira et al. 2009).
Moreover, a heterozygous nucleotide insertion in the eIF4E
promoter has been detected in two unrelated families with
two autistic siblings, likely leading to downregulation of
eIF4E (Neves-Pereira et al. 2009).
Future perspectives
In conclusion, we propose that both CYFIP1 and eIF4E could
contribute to the ASD phenotypes observed in FXS. Genetic
alterations of the FMRP-CYFIP1-eIF4E complex, as well as
other modulators of local protein synthesis, lead to cognitive
delay and behavioral disturbances, thus emphasizing that
defective local translation may underlie intellectual disability
and autism. Although the mRNAs deregulated in the absence
of FMRP have been deeply investigated so far, little informa-
tion is available concerning FMRP-CYFIP1 interactome net-
works. We believe that future studies should be addressed to
define FMRP and CYFIP1-related proteins. In fact, alterations
in the proteins co-interacting with FMRP may explain the
reduced penetrance of ASD phenotype of FXS. Moreover,
since common pathways may be implicated in related neuro-
developmental disorders, these studies may lay the ground
work for the study of novel susceptibility genes for ID and
ASD.
Acronyms
4E-BPs 4E binding proteins
AS Angelman syndrome
ASD Autism spectrum disorder
BC1 Brain cytoplasmic 1
BDNF Brain derived neurotrophic factor
CYFIP1 Cytoplasmic FMRP interacting protein 1
DHPG (S)-3,5-dihydroxyphenylglycine
eIF4E Eukaryotic initiation factor 4E
eIF4G Eukaryotic initiation factor 4 G
ERK Extracellular signal-regulated kinases
FMR1 Fragile X mental retardation 1
FMRP Fragile X mental retardation protein
FX-POI Fragile X-associated primary ovarian
insufficiency
FXS Fragile X syndrome
FXTAS Fragile X-associated tremor/ataxia syndrome
LTD Long-term depression
LTP Long-term potentiation
mGluRs Metabotropic glutamate receptors
mRNP Messenger ribonucleoparticle
mTOR Mammalian target of rapamycin
PP2A Protein phosphatase 2A
PWS Prader-Willi syndrome
RBP RNA binding protein
S6K Ribosomal protein S6 kinase
TSC2 Tuberous Sclerosis protein 2
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